US FDA’s Slow Start To Approvals In 2019: Don’t Panic
Executive Summary
US FDA approved just six new molecular entities in the first quarter of 2019, which seems like quite a letdown after a record-setting year in 2018. But don’t despair: the pattern of NME approvals was back-loaded a year ago – and should be again this year.
You may also be interested in...
Leaving On A High Note: US FDA Commissioner’s Departure Fits A Pattern
Scott Gottlieb is leaving after a record number of drug approvals. If history is any guide, his successor will likely preside over a dip in output.
CDER's Novel Approvals In 2018 Show Remarkable Review Consistency
Years of regulatory fine-tuning culminated in record low average time to approval of 9.9 months for novel agents at US FDA’s drug center.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.